BR112016021206A2 - - Google Patents
Info
- Publication number
- BR112016021206A2 BR112016021206A2 BR112016021206A BR112016021206A BR112016021206A2 BR 112016021206 A2 BR112016021206 A2 BR 112016021206A2 BR 112016021206 A BR112016021206 A BR 112016021206A BR 112016021206 A BR112016021206 A BR 112016021206A BR 112016021206 A2 BR112016021206 A2 BR 112016021206A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-092101 | 2014-04-25 | ||
| JP2014092101 | 2014-04-25 | ||
| PCT/JP2015/062520 WO2015163448A1 (ja) | 2014-04-25 | 2015-04-24 | ４環性化合物を高用量含有する製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016021206A2 true BR112016021206A2 (US07935481-20110503-C00024.png) | 2017-08-15 |
| BR112016021206B1 BR112016021206B1 (pt) | 2022-07-12 |
Family
ID=54332608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021206-1A BR112016021206B1 (pt) | 2014-04-25 | 2015-04-24 | Composição farmacêutica, contendo composto tetracíclico em dose elevada e seu método de produção |
Country Status (17)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2441753T3 (en) * | 2009-06-10 | 2016-05-30 | Chugai Pharmaceutical Co Ltd | Tetracyclic COMPOUND |
| US9365514B2 (en) | 2010-08-20 | 2016-06-14 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| NZ705705A (en) | 2012-09-25 | 2018-08-31 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| ES2724929T3 (es) | 2013-07-18 | 2019-09-17 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para la administración intermitente de un inhibidor de FGFR |
| TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥 |
| RU2020119391A (ru) | 2014-04-25 | 2020-07-03 | Чугаи Сейяку Кабусики Кайся | Получение тетрациклического соединения, содержащегося в высокой дозе |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| EP3246047A4 (en) | 2015-01-16 | 2018-08-22 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| RU2672563C1 (ru) | 2015-03-31 | 2018-11-16 | Тайхо Фармасьютикал Ко., Лтд. | Кристаллы 3,5-дизамещенного бензолалкинильного соединения |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| WO2018199282A1 (ja) * | 2017-04-28 | 2018-11-01 | アステラス製薬株式会社 | エンザルタミドを含有する経口投与用医薬組成物 |
| PT3769765T (pt) | 2018-03-19 | 2024-05-13 | Taiho Pharmaceutical Co Ltd | Composição farmacêutica incluindo alquil sulfato de sódio |
| CN112384223B (zh) | 2018-06-29 | 2024-08-27 | 中外制药株式会社 | 含有难溶性碱性药剂的药物组合物 |
| BR112021001145A2 (pt) | 2018-09-04 | 2021-04-20 | Chugai Seiyaku Kabushiki Kaisha | método para a produção de composto tetracíclico |
| AR121187A1 (es) | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene |
| CN112218626B (zh) * | 2019-12-31 | 2023-03-24 | 广州帝奇医药技术有限公司 | 一种持续释放组合物及其制备方法 |
| KR20230137321A (ko) * | 2021-01-29 | 2023-10-04 | 추가이 세이야쿠 가부시키가이샤 | 소아암 치료용 의약 조성물 |
| CN118159274A (zh) | 2021-10-28 | 2024-06-07 | 中外制药株式会社 | 糖浆剂 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4918630B1 (US07935481-20110503-C00024.png) | 1970-07-29 | 1974-05-11 | ||
| US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
| JPH0667840B2 (ja) * | 1988-11-30 | 1994-08-31 | 萬有製薬株式会社 | Ｎｂ―８１８の易吸収性製剤 |
| JPH0892090A (ja) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| EP0695755B1 (en) | 1994-08-04 | 1998-10-21 | F. Hoffmann-La Roche AG | Pyrrolocarbazole |
| JPH09202728A (ja) * | 1995-12-11 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | 固形製剤 |
| US5936084A (en) | 1996-05-01 | 1999-08-10 | Eli Lilly And Company | Halo-substituted bisindolemaleimide protein kinase C inhibitors |
| JP2002544275A (ja) | 1999-05-14 | 2002-12-24 | ジ・オーストラリアン・ナショナル・ユニバーシティー | 化合物および治療方法 |
| CA2430288C (en) | 2000-12-01 | 2009-03-10 | Kyowa Hakko Kogyo Co., Ltd. | A composition improved in the solubility or oral absorbability |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| FR2841138B1 (fr) | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
| US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| CN100398519C (zh) | 2003-02-28 | 2008-07-02 | 伊诺泰克制药公司 | 四环苯甲酰胺衍生物及其用法 |
| ATE328112T1 (de) | 2003-03-07 | 2006-06-15 | Ist Naz Stud Cura Dei Tumori | Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| US20070060595A1 (en) | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
| CN1902200A (zh) | 2003-11-21 | 2007-01-24 | 诺瓦提斯公司 | 用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物 |
| WO2005056529A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| TW200609215A (en) | 2004-03-19 | 2006-03-16 | Speedel Experimenta Ag | Organic compounds |
| CA2559866A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| AP2373A (en) | 2004-08-26 | 2012-03-07 | Pfizer | Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors. |
| US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| CN101304993A (zh) | 2005-11-07 | 2008-11-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
| RU2387650C2 (ru) | 2005-12-05 | 2010-04-27 | Пфайзер Продактс Инк. | Полиморфы с-met/hgfr ингибитора |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| KR101435229B1 (ko) * | 2006-09-14 | 2014-08-28 | 아스테라스 세이야쿠 가부시키가이샤 | 구강내 붕괴정 및 그 제조법 |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| JP2010524953A (ja) | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤 |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| CN101754956B (zh) | 2007-07-20 | 2014-04-23 | 内尔维阿诺医学科学有限公司 | 作为具有激酶抑制剂活性的取代的吲唑衍生物 |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| US20090214648A1 (en) * | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
| JP5554699B2 (ja) | 2008-03-13 | 2014-07-23 | 第一三共株式会社 | オルメサルタンメドキソミルを含む製剤の溶出性の改善 |
| JP4707073B2 (ja) * | 2008-09-30 | 2011-06-22 | アステラス製薬株式会社 | アトルバスタチン経口投与用粒子状医薬組成物 |
| AU2010244218B2 (en) | 2009-05-07 | 2012-07-19 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| DK2441753T3 (en) | 2009-06-10 | 2016-05-30 | Chugai Pharmaceutical Co Ltd | Tetracyclic COMPOUND |
| US20110311625A1 (en) * | 2010-06-14 | 2011-12-22 | Amruth Gowda Doddaveerappa | Solid dosage forms of fenofibrate |
| US9365514B2 (en) * | 2010-08-20 | 2016-06-14 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| TWI564008B (zh) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
| JP5006987B2 (ja) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| EP2694035B1 (en) * | 2011-04-06 | 2024-11-06 | Nutrition & Biosciences USA 1, LLC | Process for producing cellulose derivatives of high bulk density and good flowability |
| CA2869145A1 (en) * | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| NZ705705A (en) | 2012-09-25 | 2018-08-31 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| CA2923667A1 (en) * | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| RU2020119391A (ru) * | 2014-04-25 | 2020-07-03 | Чугаи Сейяку Кабусики Кайся | Получение тетрациклического соединения, содержащегося в высокой дозе |
| WO2015163447A1 (ja) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| KR102379639B1 (ko) | 2014-06-18 | 2022-03-28 | 에프. 호프만-라 로슈 아게 | 비이온성 계면활성제를 포함하는 약학 조성물 |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
-
2015
- 2015-04-24 RU RU2020119391A patent/RU2020119391A/ru unknown
- 2015-04-24 MY MYPI2016001752A patent/MY189913A/en unknown
- 2015-04-24 CA CA2946518A patent/CA2946518C/en active Active
- 2015-04-24 WO PCT/JP2015/062520 patent/WO2015163448A1/ja active Application Filing
- 2015-04-24 AU AU2015250574A patent/AU2015250574B2/en active Active
- 2015-04-24 TW TW109145714A patent/TWI771839B/zh active
- 2015-04-24 TW TW104113204A patent/TWI720943B/zh active
- 2015-04-24 CN CN201580020724.5A patent/CN106456651A/zh active Pending
- 2015-04-24 TW TW111104939A patent/TWI831128B/zh active
- 2015-04-24 MX MX2016013809A patent/MX2016013809A/es unknown
- 2015-04-24 US US15/304,133 patent/US10350214B2/en active Active
- 2015-04-24 CA CA3140565A patent/CA3140565C/en active Active
- 2015-04-24 AR ARP150101248A patent/AR100187A1/es not_active Application Discontinuation
- 2015-04-24 SG SG10202009484WA patent/SG10202009484WA/en unknown
- 2015-04-24 BR BR112016021206-1A patent/BR112016021206B1/pt active IP Right Grant
- 2015-04-24 CN CN202111292754.5A patent/CN113975243A/zh active Pending
- 2015-04-24 KR KR1020167031396A patent/KR102412321B1/ko active IP Right Grant
- 2015-04-24 EP EP24171823.8A patent/EP4397659A3/en active Pending
- 2015-04-24 JP JP2015530792A patent/JP5859712B1/ja active Active
- 2015-04-24 SG SG11201607623XA patent/SG11201607623XA/en unknown
- 2015-04-24 RU RU2016145057A patent/RU2724056C2/ru active
- 2015-04-24 EP EP15783124.9A patent/EP3135287A4/en active Pending
- 2015-04-24 KR KR1020227020701A patent/KR102478887B1/ko active IP Right Grant
- 2015-12-16 JP JP2015244821A patent/JP6129942B2/ja active Active
-
2016
- 2016-09-19 ZA ZA2016/06447A patent/ZA201606447B/en unknown
- 2016-10-13 IL IL248363A patent/IL248363B/en active IP Right Grant
- 2016-10-20 MX MX2021012300A patent/MX2021012300A/es unknown
-
2019
- 2019-07-11 US US16/508,760 patent/US11433076B2/en active Active
-
2020
- 2020-09-10 AU AU2020230293A patent/AU2020230293B2/en active Active
-
2021
- 2021-05-12 IL IL283152A patent/IL283152B2/en unknown
-
2022
- 2022-07-29 US US17/877,542 patent/US20220378800A1/en not_active Abandoned
- 2022-08-26 US US17/896,758 patent/US20230105990A1/en active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/04/2015, OBSERVADAS AS CONDICOES LEGAIS |